Verastem, Inc. (VSTM)
| Market Cap | 653.87M +14.4% |
| Revenue (ttm) | 87.53M +3,995.7% |
| Net Income | -202.70M |
| EPS | -2.28 |
| Shares Out | 90.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,084,339 |
| Open | 7.32 |
| Previous Close | 7.38 |
| Day's Range | 7.18 - 7.38 |
| 52-Week Range | 3.43 - 11.25 |
| Beta | 0.29 |
| Analysts | Strong Buy |
| Price Target | 14.75 (+104.29%) |
| Earnings Date | Aug 6, 2026 |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki... [Read more]
Financial Performance
In 2025, Verastem's revenue was $30.91 million, an increase of 209.14% compared to the previous year's $10.00 million. Losses were -$209.47 million, 60.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price target is $14.75, which is an increase of 104.29% from the latest price.
News
Verastem price target lowered to $13 from $14 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Verastem (VSTM) to $13 from $14 and keeps an Outperform rating on the shares. The firm updated the company’s model…
Verastem price target lowered to $13 from $14 at Mizuho
Mizuho lowered the firm’s price target on Verastem (VSTM) to $13 from $14 and keeps an Outperform rating on the shares following last week’s Q2 report. The firm leaves Q2…
Verastem price target lowered to $12 from $14 at Guggenheim
Guggenheim lowered the firm’s price target on Verastem (VSTM) to $12 from $14 and keeps a Buy rating on the shares after updating the firm’s model following Q2 results. Published…
Verastem Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth and expanded adoption of AVMAPKI FAKZYNJA CO-PACK, supported by robust commercial execution and $90 million in non-dilutive funding. Clinical pipeline advanced with positive data and FDA Fast Track for VS-7375, with key data updates expected in October.
Verastem Earnings release: Q2 2026
Verastem released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Verastem Quarterly report: Q2 2026
Verastem has published its Q2 2026 quarterly earnings report on August 6, 2026.
Verastem Slides: Q2 2026
Verastem has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Verastem reports Q2 adjusted EPS (31c), consensus (44c)
Reports Q2 revenue $40.1M, consensus $22.88M. “The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI F...
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial ...
Verastem Slides: Corporate presentation
Verastem has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Verastem doses first patients in Target-D 203 Phase 2 trial
Verastem (VSTM) Oncology “announced that the first patient has been dosed in the TARGET-D 203 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibit...
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 203, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated metastatic colorectal cancer.
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Verastem doses first patient in TARGET-D 202 Phase 2 trial
Verastem (VSTM) Oncology announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, in pat...
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated advanced NSCLC.
Verastem price target lowered to $14 from $15 at RBC Capital
RBC Capital lowered the firm’s price target on Verastem (VSTM) to $14 from $15 and keeps an Outperform rating on the shares as part of a broader research note previewing…
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant...
Verastem Transcript: Study update
VS-7375, a selective oral KRAS G12D inhibitor, shows promising efficacy and tolerability in phase I/II trials for pancreatic, colorectal, and lung cancers, with deep responses and manageable side effects at 900 mg. Combination strategies and pivotal trials are advancing rapidly.
Verastem Press release: Study update
Verastem issued a press release on June 23, 2026, disclosing material business information to investors.
Verastem Slides: Study update
Verastem has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial
Verastem (VSTM) Oncology announced positive preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, with best-in-class ...
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial.
Verastem price target lowered to $8 from $15 at Jefferies
Jefferies lowered the firm’s price target on Verastem (VSTM) to $8 from $15 and keeps a Buy rating on the shares. The long pitch on Verastem is “growing less attractive”…
Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study
Verastem (VSTM) Oncology announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose cohort of 29 patients evaluating avutometinib plus defactinib in ...
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem Oncology announces updated results from RAMP 205 clinical trial in first-line metastatic pancreatic ductal adenocarcinoma.